Johnson & Johnson Investor Presentation — November 2022

Document content

Announces Acquisition

Conference Call to Begin at 8:00 AM ET

1Johnson & Johnson +

Investor Presentation

Chief Executive Officer of

Johnson & JohnsonAshley McEvoy

Executive Vice President and

Worldwide Chairman of

MedTech at Johnson &

Chief Financial Officer of

Johnson & JohnsonMichael Minogue

Chairman, President and

Chief Executive Officer of

Cautionary Note on Forward Looking Statements

4Additional InformationThis presentation contains forward -looking statements regarding the potential acquisition of ABIOMED. The reader is cautioned n ot to rely on these forward -looking statements. These

statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknow n risks or uncertainties materialize, actual results could vary

materially from the expectations and projections of ABIOMED or Johnson & Johnson. Risks and uncertainties include, but are n ot limited to: the risk that the closing conditions for the

acquisition will not be satisfied, including the risk that clearance under the Hart -Scott -Rodino Antitrust Improvements Act or other applicable antitrust laws will not be obtained; uncertainty as to

the percentage of ABIOMED stockholders that will support the proposed transaction and tender their outstanding shares of comm on stock of ABIOMED in the Offer; the possibility that the

transaction will not be completed in the expected timeframe or at all; potential adverse effects to the businesses of Johnson & Johnson or ABIOMED during the pendency of the transaction,

such as employee departures or distraction of management from business operations; the risk of stockholder litigation relatin g to the transaction, including resulting expense or delay; the